Yelena Y. Janjigian, MD

Yelena Y. Janjigian, MD, is chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

Articles

Ongoing Research to Watch in Advanced Gastric/GEJ Cancer

December 1st 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.

Other Key Data in Gastric/GEJ Cancer Presented at ESMO 2025

December 1st 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss other key gastric cancer data presented at the 2025 ESMO Congress.

Where Domvanalimab/Zimberelimab/Chemo Could Fit in the Advanced Gastric/GEJ/Esophageal Adenocarcinoma Paradigm

November 24th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the potential clinical implications of the investigation of domvanalimab plus zimberelimab and FOLFOX in gastric/GEJ/esophageal adenocarcinoma.

Detailing the Ongoing Phase 3 STAR-221 Trial of Domvanalimab/Zimberelimab Plus FOLFOX in First-Line Gastric/GEJ/Esophageal Adenocarcinoma

November 24th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, detail the design of the phase 3 STAR-221 trial comparing domvanalimab plus zimberelimab and FOLFOX with nivolumab plus chemotherapy for first-line advanced gastric, GEJ, or esophageal adenocarcinoma. They discuss why nivolumab plus chemotherapy serves as an appropriate control arm and the importance of head-to-head evidence in clarifying comparative benefit across immunotherapy combinations. They review the study’s primary endpoints and overall goals, including survival outcomes and the potential to redefine the frontline standard.

EDGE-Gastric Trial: Breaking Down Data for Domvanalimab/Zimberelimab Plus Chemo in First-Line Gastric/GEJ/Esophageal Adenocarcinoma

November 17th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the implications of findings from the phase 2 EDGE-Gastric trial.

Current Standards and Unmet needs in Advanced Gastric/GEJ Cancer

November 17th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss current treatment standards in advanced gastric/GEJ cancer.

Updated Results from the EDGE-Gastric Arm A1 Study

November 11th 2025

Summarize long-term results from the phase 2 EDGE-Gastric Arm A1 study evaluating domvanalimab (anti-TIGIT) + zimberelimab (anti-PD-1) + FOLFOX as first-line therapy for advanced HER2-negative gastric, GEJ, or esophageal adenocarcinoma. Key data shown include ORR, PFS, OS, and safety outcomes, demonstrating encouraging clinical activity and manageable toxicity, along with context regarding the ongoing phase 3 STAR-221 trial.

Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma

July 4th 2025

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

Dr Janjigian on the Efficacy of Durvalumab Plus Chemotherapy in Resectable GEJ Adenocarcinoma

June 24th 2025

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

Event-free Survival (EFS) in MATTERHORN: A Randomized, Phase 3 Study of Durvalumab plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Chemotherapy (FLOT) in Resectable Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

June 23rd 2025

Presented by Yelena Y. Janjigian at ASCO 2025, the Phase 3 MATTERHORN study demonstrated that adding durvalumab to FLOT significantly improved event-free survival compared with FLOT alone in patients with resectable gastric and gastroesophageal junction adenocarcinoma, with consistent benefit across subgroups and no new safety concerns.

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

June 19th 2025

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Dr Janjigian on Safety Considerations With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

May 19th 2025

Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.

Dr Janjigian on Future Research Directions for Immunotherapy in Gastric/GEJ/Esophageal Cancer

May 15th 2025

Yelena Y. Janjigian, MD, discusses future research directions with nivolumab-based treatments in gastric, GEJ, and esophageal cancer.

Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

February 24th 2025

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

November 22nd 2024

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Dr Janjigian on Final OS Results With Pembrolizumab Plus Trastuzumab and Chemo in HER2+ Gastric/GEJ Cancer

October 7th 2024

Yelena Y. Janjigian, MD, discusses final overall survival data from the phase 3 KEYNOTE-811 trial in HER2-positive metastatic gastric or GEJ adenocarcinoma.

Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study

January 30th 2024

Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Dr Janjigian on Pembrolizumab/Trastuzumab/Chemotherapy in HER2+ Gastric Cancer

October 28th 2023

Yelena Y. Janjigian, MD, discusses results from the primary progression-free survival and interim overall survival analyses of the phase 3 KEYNOTE-811 trial in patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, and contextualizes these findings with previously reported data from this trial.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649

February 10th 2023

Yelena Y. Janjigian, MD, reviews the 3-year follow-up data from the CheckMate 649 trial investigating nivolumab plus chemotherapy as a first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.